JOHNSON CITY, Tenn., Aug. 7, 2025 /PRNewswire/ -- As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to announce our partnership with Kits4Life, an initiative of the MedSurplus Alliance. This collaboration reflects our broader ESG strategy and strengthens LabConnect's role as the world's most agile and responsible central laboratory services provider. Through this partnership, LabConnect will work with sponsors and clinical sites to identify and manage eligible kits for donation, reducing landfill waste while contributing to global health equity.
Clinical trials are essential to developing life-changing therapies, but they can also generate significant material waste—particularly unused and expired specimen collection kits. These kits often contain high-quality medical materials that, when responsibly redirected, can have a second life in communities with critical healthcare needs. "We are excited to partner with Kits4Life as a framework for recovering surplus clinical trial kits and ensuring they are ethically and safely donated to organizations," states Julia Tarasenko, Chief Commercial & Strategy Officer at LabConnect.
LabConnect's ESG strategy focuses on transforming clinical trials into a more sustainable and inclusive global enterprise. From carbon footprint reduction to ethical sourcing and community engagement, we are integrating environmental and social responsibility across the full lifecycle of clinical research. Our work with Kits4Life is one more way we are turning strategy into action—by diverting valuable materials from waste streams and redirecting them to improve lives.
"We believe that sustainability and scientific innovation are not mutually exclusive—they are mutually reinforcing. As the clinical research industry evolves, partnerships like this help chart a path forward where environmental responsibility and breakthrough therapies go hand in hand," adds Tarasenko.
About LabConnect
LabConnect is the leading provider of Central Laboratory Services, FSP and Scientific Consulting, and Data Integration and Transformation Services for analytically and logistically complex studies such as immuno-oncology, cell and gene therapies, and rare & orphan diseases.
LabConnect's unique combination of state-of-the-art technology, world-class laboratories, easy access to major and emerging markets, and extensive specialized testing expertise means that drug development companies can rely on one provider for all their central laboratory service needs.
Learn more at www.labconnect.com and follow on LinkedIn.
Logo - https://mma.prnewswire.com/media/2611513/LabConnect_Logo.jpg
Comunicato stampa sponsorizzato - Responsabilità editoriale PrNewswire. I giornalisti Adnkronos non sono in nessun modo coinvolti né responsabili per i contenuti dei comunicati trasmessi.
.jpg)
.jpg)
